Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Receivables (2022 - 2025)

Historic Receivables for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $1.9 million.

  • Atara Biotherapeutics' Receivables rose 4329.59% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 4329.59%. This contributed to the annual value of $1.5 million for FY2024, which is 9565.5% down from last year.
  • Atara Biotherapeutics' Receivables amounted to $1.9 million in Q3 2025, which was up 4329.59% from $8.9 million recorded in Q1 2025.
  • Atara Biotherapeutics' Receivables' 5-year high stood at $40.2 million during Q4 2022, with a 5-year trough of $163000.0 in Q3 2023.
  • Moreover, its 4-year median value for Receivables was $1.4 million (2024), whereas its average is $9.2 million.
  • Data for Atara Biotherapeutics' Receivables shows a peak YoY increase of 892619.65% (in 2024) and a maximum YoY decrease of 9565.5% (in 2024) over the last 5 years.
  • Over the past 4 years, Atara Biotherapeutics' Receivables (Quarter) stood at $40.2 million in 2022, then fell by 15.2% to $34.1 million in 2023, then crashed by 95.65% to $1.5 million in 2024, then grew by 29.08% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $8.9 million for Q1 2025, and $1.5 million during Q4 2024.